Interestingly, leukemic cells in the primitive subtype are more sensitive to certain kinase inhibitors and the addition of kinase inhibitors to the treatment might achieve benefits in this subtype of NPM1-mutated AML. The gene discussed is NPM1; the disease is acute myeloid leukemia.